AIM ImmunoTech Inc. (AIM) Stock Forecast
AIM analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 2 analysts
- Price target
- $4.25 average of analyst targets
- Upside to target
- +2,428.3% from the latest close
- Next earnings
- November 16, 2026 EPS estimate $-0.09
- 52-week range
- $0.16 – $2.76
AIM analyst ratings
2 analystsNumber of analysts at each rating.
AIM price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
AIM earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.09 | −$0.09 | −$0.09 | −$1.57 | +94.3% | 1 |
| Current fiscal year (2026) | −$0.78 | −$0.78 | −$0.78 | −$8.62 | +91.0% | 1 |
| Next fiscal year (2027) | −$0.37 | −$0.37 | −$0.37 | −$0.78 | +52.6% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
AIM revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | −100.0% | 2 |
| Current fiscal year (2026) | $74,000 | $48,000 | $100,000 | −15.9% | 2 |
| Next fiscal year (2027) | $50,000 | $0 | $100,000 | −32.4% | 2 |
AIM EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
AIM revenue: reported and forecast
AIM EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.37 | −$0.12 | −$0.12 | −$0.12 | −$0.09 | −75.7% | 1 up · 0 down |
| Current fiscal year (2026) | −$1.47 | −$0.63 | −$0.63 | −$0.63 | −$0.78 | −46.9% | 0 up · 1 down |
| Next fiscal year (2027) | −$1.47 | −$0.52 | −$0.52 | −$0.52 | −$0.37 | −74.8% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
AIM earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; AIM beat in 5 of 12.
What analysts expect from AIM
2 analysts cover AIM ImmunoTech; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $4.25, 2,428.3% above the latest close of $0.17. Analysts expect earnings of −$0.78 per share for 2026, +91.0% from a year earlier. For 2027 the average estimate is −$0.37 per share on revenue of $0.1 million. AIM ImmunoTech beat the EPS estimate in 5 of the last 12 quarters.
Related: AIM income statement, AIM key metrics, AIM chart. See the AIM stock overview for the latest quote and news.
AIM forecast FAQ
What is AIM ImmunoTech's price target?
The average analyst price target for AIM ImmunoTech is $4.25, 2,428.3% above the latest close of $0.17.
Is AIM ImmunoTech a buy, hold or sell?
Of 2 analysts covering AIM ImmunoTech, 1 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is AIM ImmunoTech's EPS forecast?
Analysts forecast −$0.78 per share for 2026 (range −$0.78 to −$0.78); for 2027 the estimate is −$0.37.
What is AIM ImmunoTech's revenue forecast?
The average revenue estimate for 2026 is $0.1 million, growth of −15.9%; for 2027 it is $0.1 million.
When does AIM ImmunoTech report earnings?
AIM ImmunoTech is expected to report results for the quarter ending September 30, 2026 on November 16, 2026; the EPS estimate is $-0.09.
Does AIM ImmunoTech usually beat earnings estimates?
AIM ImmunoTech reported EPS at or above the analyst estimate in 5 of the last 12 quarters.